People with HIV who experienced extensive immune deficiency or who used early antiretroviral drugs before the advent of combination highly-active antiretroviral therapy (HAART) in the mid-90s may be at greater risk for developing anal cancer, according to a retrospective analysis published in the January 28 edition of AIDS.
23 January 2015 | HIVandHepatitis.com
A CDC recommendation report issued by the Advisory Committee on Immunization Practices released late this summer calls for a better understanding of anal cancer development and screening among a population at high risk—men who have sex with men (MSM). Although there’s still uncertainty about the best way to screen for and treat anal cancer, here’s what we know right now about who gets it, and what to look out for if you’re worried.
14 January 2015 | BETA blog
Experiments in mice and in humans have indicated that the HIV drug maraviroc (Celsentri/Selzentry) could be used to prevent the spread of metastases (secondary caners) from prostate and other cancers. Experiments in mice showed a 60% reduction in metastases in animals treated with maraviroc.
04 January 2015 | Medical news today
A recent study claims to be the first to have established the association of oral infection in males with sexual behaviour, not just on the basis of their reported sexual behaviour, but through the collection of data from their partners.
15 December 2014 | BMJ Blogs
HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.
10 December 2014 | Science Daily
Sexual behavior of teenage girls does not appear to be impacted by the human papilloma virus (HPV) vaccine, according to Queen's University, Canada researchers Drs. Leah Smith and Linda Lévesque.
09 December 2014 | Eurekalert
HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology (ASH) meetings, show the concern of additional risk is unfounded.
08 December 2014 | Business Wire (press release)
Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. The receptor CCR5, targeted by HIV drugs, is also key in driving prostate cancer metastases, suggesting that blocking this molecule could slow prostate cancer spread.
02 December 2014 | Science Daily
The HPV vaccine should be given to men who have sex with men, according to the government's experts. It is is already given to schoolgirls in the UK, but there have been calls for the vaccination programme to be extended. The Joint Committee on Vaccination and Immunisation now recommends offering the jab at sexual health clinics to men who have sex with men, aged between 16 and 40.
12 November 2014 | BBC News
Study participants who reported tobacco use or had higher levels of biomarkers of tobacco exposure had a higher prevalence of the sexually transmitted infection, oral human papillomavirus type 16, according to a study in the Oct. 8 JAMA, a theme issue on infectious disease. HPV-16 is the most common cancer-causing variety of HPV.
08 October 2014 | Eurekalert